Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study.

DiMeglio LA, Kanapka LG, DeSalvo DJ, Anderson BJ, Harrington KR, Hilliard ME, Laffel LM, Tamborlane WV, Van Name MA, Wadwa RP, Willi SM, Woerner S, Wong JC, Miller KM; SENCE Study Group.

Diabet Med. 2020 Feb 24. doi: 10.1111/dme.14276. [Epub ahead of print]

PMID:
32096282
2.

Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes.

DuBose SN, Li Z, Sherr JL, Beck RW, Tamborlane WV, Shah VN.

J Diabetes Sci Technol. 2020 Feb 17:1932296820905904. doi: 10.1177/1932296820905904. [Epub ahead of print]

PMID:
32064911
3.

Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control.

Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV; Pediatric Diabetes Consortium.

Diabet Med. 2020 Jan 14. doi: 10.1111/dme.14233. [Epub ahead of print]

PMID:
31943374
4.

Executive task-based brain function in children with type 1 diabetes: An observational study.

Foland-Ross LC, Buckingam B, Mauras N, Arbelaez AM, Tamborlane WV, Tsalikian E, Cato A, Tong G, Englert K, Mazaika PK, Reiss AL; Diabetes Research in Children Network (DirecNet).

PLoS Med. 2019 Dec 9;16(12):e1002979. doi: 10.1371/journal.pmed.1002979. eCollection 2019 Dec.

5.

"I'm essentially his pancreas": Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes.

Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM.

Pediatr Diabetes. 2020 Mar;21(2):377-383. doi: 10.1111/pedi.12956. Epub 2019 Dec 16.

PMID:
31808586
6.

Liraglutide in Children and Teens with Type 2 Diabetes. Reply.

Tamborlane WV, Fainberg U, Barrett T.

N Engl J Med. 2019 Oct 31;381(18):1787. doi: 10.1056/NEJMc1912498. No abstract available.

PMID:
31665592
7.

Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring.

Van Name MA, Miller KM, Commissariat PV, Whitehouse AL, Harrington KR, Anderson BJ, Mantravadi MG, Levy W, DeSalvo DJ, Tamborlane WV, Hilliard ME, Laffel LM, DiMeglio LA.

Diabet Med. 2019 Nov;36(11):1508-1510. doi: 10.1111/dme.14074. Epub 2019 Jul 25. No abstract available.

PMID:
31295359
8.

Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes.

Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, Laffel LM, Miller KM, Van Name M, Tamborlane WV, DeSalvo DJ, DiMeglio LA.

Diabetes Technol Ther. 2019 Sep;21(9):493-498. doi: 10.1089/dia.2019.0142. Epub 2019 Jul 9.

PMID:
31287721
9.

Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network.

McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR.

J Diabetes Complications. 2019 Oct;33(10):107400. doi: 10.1016/j.jdiacomp.2019.06.005. Epub 2019 Jun 26.

PMID:
31279735
10.

Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self-management behaviors in adolescents with type 1 diabetes.

Wagner JA, Petry NM, Weyman K, Tichy E, Cengiz E, Zajac K, Tamborlane WV.

Pediatr Diabetes. 2019 Nov;20(7):997-1006. doi: 10.1111/pedi.12889. Epub 2019 Jul 17.

PMID:
31271239
11.

Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?

Gubitosi-Klug RA, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group*.

Pediatr Diabetes. 2019 Sep;20(6):743-749. doi: 10.1111/pedi.12877. Epub 2019 Jul 9.

PMID:
31206973
12.

Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study.

Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4356-4364. doi: 10.1210/jc.2018-02763.

PMID:
31127824
13.

Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics.

Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV.

J Diabetes Sci Technol. 2019 Nov;13(6):1123-1128. doi: 10.1177/1932296819842151. Epub 2019 May 8.

PMID:
31067999
14.

Liraglutide in Children and Adolescents with Type 2 Diabetes.

Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators.

N Engl J Med. 2019 Aug 15;381(7):637-646. doi: 10.1056/NEJMoa1903822. Epub 2019 Apr 28.

PMID:
31034184
15.

IMPACT OF SWITCHING YOUTH WITH DIABETES TO INSULIN DEGLUDEC IN CLINICAL PRACTICE.

Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA.

Endocr Pract. 2019 Mar;25(3):226-229. doi: 10.4158/EP-2018-0417.

PMID:
30913005
16.

Pharmacologic treatment options for type 1 diabetes: what's new?

Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV.

Expert Rev Clin Pharmacol. 2019 May;12(5):471-479. doi: 10.1080/17512433.2019.1597705. Review.

PMID:
30892094
17.

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M.

Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6. Review.

PMID:
30728224
18.

Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.

Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL.

Diabetes Technol Ther. 2019 Mar;21(3):101-104. doi: 10.1089/dia.2018.0356. Epub 2019 Jan 28.

PMID:
30688521
19.

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.

Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK.

Diabetes Technol Ther. 2019 Feb;21(2):66-72. doi: 10.1089/dia.2018.0384. Epub 2019 Jan 18. Erratum in: Diabetes Technol Ther. 2019 Apr;21(4):230.

PMID:
30657336
20.

Substance Use in Adults With Type 1 Diabetes in the T1D Exchange.

Petry NM, Foster NC, Cengiz E, Tamborlane WV, Wagner J, Polsky S.

Diabetes Educ. 2018 Dec;44(6):510-518. doi: 10.1177/0145721718799088. Epub 2018 Sep 11.

PMID:
30203721
21.

Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry.

Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW; Pediatric Diabetes Consortium.

Pediatr Diabetes. 2018 Dec;19(8):1379-1384. doi: 10.1111/pedi.12763. Epub 2018 Oct 10.

PMID:
30175440
22.

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.

Bjornstad P, Laffel L, Tamborlane WV, Simons G, Hantel S, von Eynatten M, George J, Marquard J, Cherney DZI.

Diabetes Care. 2018 Aug;41(8):e129-e130. doi: 10.2337/dc18-0394. Epub 2018 Jun 25. No abstract available.

23.

Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology.

Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L.

Diabetes Care. 2018 Jul;41(7):1327-1329. doi: 10.2337/dci18-0035. No abstract available.

PMID:
29934474
24.

Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries.

Klingensmith GJ, Lanzinger S, Tamborlane WV, Hofer SE, Cheng P, de Beaufort C, Gal RL, Reinehr T, Kollman C, Holl RW.

Pediatr Diabetes. 2018 Nov;19(7):1156-1163. doi: 10.1111/pedi.12712. Epub 2018 Jul 17.

PMID:
29923263
25.

Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.

Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J.

Diabet Med. 2018 Aug;35(8):1096-1104. doi: 10.1111/dme.13629. Epub 2018 May 6.

26.

Persistence of abnormalities in white matter in children with type 1 diabetes.

Fox LA, Hershey T, Mauras N, Arbeláez AM, Tamborlane WV, Buckingham B, Tsalikian E, Englert K, Raman M, Jo B, Shen H, Reiss A, Mazaika P; Diabetes Research in Children Network (DirecNet).

Diabetologia. 2018 Jul;61(7):1538-1547. doi: 10.1007/s00125-018-4610-6. Epub 2018 Apr 13.

27.

Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.

Tamborlane WV, Polidori D, Argenti D, Di Prospero NA.

Pediatr Diabetes. 2018 Jun;19(4):649-655. doi: 10.1111/pedi.12626. Epub 2017 Dec 22.

PMID:
29271103
28.

Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.

Tamborlane WV, Laffel LM, Weill J, Gordat M, Neubacher D, Retlich S, Hettema W, Hoesl CE, Kaspers S, Marquard J.

Pediatr Diabetes. 2018 Jun;19(4):640-648. doi: 10.1111/pedi.12616. Epub 2017 Nov 24.

PMID:
29171139
29.

International Consensus on Use of Continuous Glucose Monitoring.

Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M.

Diabetes Care. 2017 Dec;40(12):1631-1640. doi: 10.2337/dc17-1600. Review.

30.

Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry.

Bacha F, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Manseau K, Wood J, Beck RW; for the Pediatric Diabetes Consortium.

Horm Res Paediatr. 2018;89(1):47-55. doi: 10.1159/000481687. Epub 2017 Oct 31.

PMID:
29131017
31.

Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.

Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL.

Diabetes Technol Ther. 2017 Nov;19(11):618-622. doi: 10.1089/dia.2017.0267. Epub 2017 Oct 25.

32.

Continuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial.

Galderisi A, Facchinetti A, Steil GM, Ortiz-Rubio P, Cavallin F, Tamborlane WV, Baraldi E, Cobelli C, Trevisanuto D.

Pediatrics. 2017 Oct;140(4). pii: e20171162. doi: 10.1542/peds.2017-1162. Epub 2017 Sep 15.

33.

POSTPRANDIAL DOSING OF BOLUS INSULIN IN PATIENTS WITH TYPE 1 DIABETES: A CROSS-SECTIONAL STUDY USING DATA FROM THE T1D EXCHANGE REGISTRY.

Peters A, Van Name MA, Thorsted BL, Piltoft JS, Tamborlane WV.

Endocr Pract. 2017 Oct;23(10):1201-1209. doi: 10.4158/EP171813.OR. Epub 2017 Jul 13.

PMID:
28704103
34.

Insulin Pump Use in Young Children with Type 1 Diabetes: Sociodemographic Factors and Parent-Reported Barriers.

Commissariat PV, Boyle CT, Miller KM, Mantravadi MG, DeSalvo DJ, Tamborlane WV, Van Name MA, Anderson BJ, DiMeglio LA, Laffel LM.

Diabetes Technol Ther. 2017 Jun;19(6):363-369. doi: 10.1089/dia.2016.0375. Epub 2017 Jun 5.

35.

Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.

Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

Diabetes Care. 2017 Aug;40(8):1010-1016. doi: 10.2337/dc16-2723. Epub 2017 May 26.

36.

Predictors of Loss to Follow-Up among Children with Type 2 Diabetes.

Shoemaker A, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Clements MA, Hannon TS, Heptulla R, Less J, Wood J; for the Pediatric Diabetes Consortium.

Horm Res Paediatr. 2017;87(6):377-384. doi: 10.1159/000475595. Epub 2017 May 15.

37.

Nighttime is the worst time: Parental fear of hypoglycemia in young children with type 1 diabetes.

Van Name MA, Hilliard ME, Boyle CT, Miller KM, DeSalvo DJ, Anderson BJ, Laffel LM, Woerner SE, DiMeglio LA, Tamborlane WV.

Pediatr Diabetes. 2018 Feb;19(1):114-120. doi: 10.1111/pedi.12525. Epub 2017 Apr 21.

38.

Schooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings.

Erie C, Van Name MA, Weyman K, Weinzimer SA, Finnegan J, Sikes K, Tamborlane WV, Sherr JL.

Pediatr Diabetes. 2018 Feb;19(1):92-97. doi: 10.1111/pedi.12518. Epub 2017 Mar 17.

39.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Mar;19(3):155-163. doi: 10.1089/dia.2016.0421. Epub 2017 Jan 30.

40.

Substance Use Disorders among Patients with Type 2 Diabetes: a Dangerous but Understudied Combination.

Walter KN, Wagner JA, Cengiz E, Tamborlane WV, Petry NM.

Curr Diab Rep. 2017 Jan;17(1):2. doi: 10.1007/s11892-017-0832-0. Review.

PMID:
28101793
41.

Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin.

Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M.

Curr Med Res Opin. 2017 Apr;33(4):639-645. doi: 10.1080/03007995.2016.1275937. Epub 2017 Jan 24.

PMID:
28008782
42.

Diabetes Care: "Taking It to the Limit One More Time".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC.

Diabetes Care. 2017 Jan;40(1):3-6. doi: 10.2337/dc16-2326. No abstract available.

43.

Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study.

Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL.

Diabetes Technol Ther. 2016 Dec;18(12):794-799.

44.

Treatable Diabetic Retinopathy Is Extremely Rare Among Pediatric T1D Exchange Clinic Registry Participants.

Beauchamp G, Boyle CT, Tamborlane WV, Miller KM, Libman IM, Haller MJ, Beck RW; T1D Exchange Clinic Network.

Diabetes Care. 2016 Dec;39(12):e218-e219. Epub 2016 Oct 7. No abstract available.

45.

Disordered Eating Behaviors in Emerging Adults With Type 1 Diabetes: A Common Problem for Both Men and Women.

Doyle EA, Quinn SM, Ambrosino JM, Weyman K, Tamborlane WV, Jastreboff AM.

J Pediatr Health Care. 2017 May - Jun;31(3):327-333. doi: 10.1016/j.pedhc.2016.10.004. Epub 2016 Nov 11.

PMID:
27843015
46.

Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes.

Farrell R, Bethin K, Klingensmith G, Tamborlane WV, Gubitosi-Klug R.

Pediatr Diabetes. 2017 Nov;18(7):574-578. doi: 10.1111/pedi.12465. Epub 2016 Nov 3.

PMID:
27807915
47.

Vitamin D status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes Consortium (PDC) is not worse than in youth without diabetes.

Wood JR, Connor CG, Cheng P, Ruedy KJ, Tamborlane WV, Klingensmith G, Schatz D, Gregg B, Cengiz E, Willi S, Bacha F, Beck RW; Pediatric Diabetes Consortium.

Pediatr Diabetes. 2016 Dec;17(8):584-591. doi: 10.1111/pedi.12340. Epub 2015 Nov 26.

48.

Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study.

Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, Klingensmith GJ, Gal RL, Silverstein J, Lee J, Redondo MJ, Beck RW; Pediatric Diabetes Consortium.

Pediatr Diabetes. 2017 Nov;18(7):566-573. doi: 10.1111/pedi.12459. Epub 2016 Oct 19.

49.

No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year.

Sherr JL, Boyle CT, Miller KM, Beck RW, Tamborlane WV; T1D Exchange Clinic Network.

Diabetes Care. 2016 Dec;39(12):e214-e215. Epub 2016 Oct 4. No abstract available.

50.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

Supplemental Content

Loading ...
Support Center